Equity Profile

TECH

Bio-Techne Corporation

Health CareLife Sciences Tools & Services$8.1B

Aug5Wed

Pre-Earnings Brief

UpcomingQ4-2026Pre-Market9:00 AM EDT

Company Snapshot

Bio-Techne Corporation operates in the health care sector, focusing on life sciences tools and services. The company provides essential products and technologies for research and clinical diagnostics, making it significant in advancing medical science and improving patient care.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well the company is managing its costs and generating income.

N/A

Revenue Growth

Revenue growth is critical for assessing the company's ability to expand its market share and product offerings.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

TECH Q4-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+20.74%

Avg Stock Reaction

-2.11%

Last Quarter Recap

In Q3-2026, Bio-Techne reported an EPS of $0.53, exceeding expectations by 11.11%. However, the stock dropped 16.36% the following day, indicating market concerns despite the earnings beat.

Management Promises & Guidance

Focus on expanding product lines in life sciences.
Commitment to improving operational efficiency.
Plans to enhance customer engagement and support.

Expectations

Wall Street Expectations

Investors are cautiously optimistic about Bio-Techne's upcoming earnings, given its history of beating EPS estimates. However, the recent stock price volatility raises concerns about future performance.

Bull Case

If Bio-Techne continues its trend of beating EPS estimates, it could signal strong operational performance and market confidence, potentially leading to a stock price rebound.

Bear Case

On the other hand, if the company fails to meet expectations or provides weak guidance, it could lead to further declines in stock price, especially given the recent negative reaction to earnings.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q4-2026?

Given the company's history of beating EPS estimates, this number will be crucial for investor confidence and stock performance.

What guidance will management provide for revenue growth?

Future revenue growth expectations will influence market sentiment and the stock's trajectory post-earnings.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Bio-Techne's ability to maintain its growth trajectory despite recent stock volatility. The company's strong history of beating EPS estimates suggests it could surprise investors positively this quarter.

Supporting Evidence

The company has consistently beaten EPS estimates in the past, indicating strong operational management.

Options pricing suggests a significant move, reflecting trader expectations of volatility.

The recent stock price drop may have created an overly cautious sentiment among investors.

Key Risk

If the EPS comes in below $0.50, it could validate concerns about the company's growth potential.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The upcoming earnings report is critical as it will either reinforce the company's growth narrative or raise concerns about its future prospects.

Bull Confirmed If

An EPS of $0.55 or higher would confirm strong operational performance and market confidence.

Bear Confirmed If

An EPS below $0.50 could indicate underlying issues and lead to a negative market reaction.

Pre-Earnings Positioning

Options Market

Implied Move

±7.13%

Historical Avg

±7.0%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±30.7% while TECH has averaged ±7.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

80.0%

Calls (15K)P/C Ratio: 0.01Puts (4K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: X of Y (Z%)

This setup has occurred 30 times across Health Care in the last 2 years. The average absolute 1-day move is 4.6%, with a raw directional average of +0.1% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Bio-Techne beats expectations, history suggests the stock could rise, potentially by around 6.86% based on past reactions.

In-Line / Cautious

If results are in line with expectations but management's commentary is cautious, the stock may see muted movement as investors reassess their outlook.

Miss

If the company misses expectations, history suggests a potential decline of around 2.11%, reflecting investor disappointment.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

0 buys·3 sells

Members

House only

Est. Notional

$3,003.00–$45,000.00

disclosed dollar ranges

Most Active Members

D-MDApril McClain DelaneyRep.
3

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches in the life sciences sector.
2Management's commentary on operational efficiency improvements.
3Insights into customer engagement strategies and their effectiveness.
4Guidance on revenue growth expectations for the upcoming quarters.
5Responses to market conditions affecting the health care sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well the company is managing its costs and generating income.

N/A

Revenue Growth

Revenue growth is critical for assessing the company's ability to expand its market share and product offerings.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

TECH Q4-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+20.74%

Avg Stock Reaction

-2.11%

Last Quarter Recap

In Q3-2026, Bio-Techne reported an EPS of $0.53, exceeding expectations by 11.11%. However, the stock dropped 16.36% the following day, indicating market concerns despite the earnings beat.

Management Promises & Guidance

Focus on expanding product lines in life sciences.
Commitment to improving operational efficiency.
Plans to enhance customer engagement and support.

Expectations

Wall Street Expectations

Bull Case

If Bio-Techne continues its trend of beating EPS estimates, it could signal strong operational performance and market confidence, potentially leading to a stock price rebound.

Bear Case

On the other hand, if the company fails to meet expectations or provides weak guidance, it could lead to further declines in stock price, especially given the recent negative reaction to earnings.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q4-2026?

Given the company's history of beating EPS estimates, this number will be crucial for investor confidence and stock performance.

What guidance will management provide for revenue growth?

Future revenue growth expectations will influence market sentiment and the stock's trajectory post-earnings.

Edge

What the Street Is Missing

Why consensus could be wrong

Supporting Evidence

The company has consistently beaten EPS estimates in the past, indicating strong operational management.

Options pricing suggests a significant move, reflecting trader expectations of volatility.

The recent stock price drop may have created an overly cautious sentiment among investors.

Key Risk

If the EPS comes in below $0.50, it could validate concerns about the company's growth potential.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The upcoming earnings report is critical as it will either reinforce the company's growth narrative or raise concerns about its future prospects.

Bull Confirmed If

An EPS of $0.55 or higher would confirm strong operational performance and market confidence.

Bear Confirmed If

An EPS below $0.50 could indicate underlying issues and lead to a negative market reaction.

Pre-Earnings Positioning

Options Market

Implied Move

±7.13%

Historical Avg

±7.0%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±30.7% while TECH has averaged ±7.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

80.0%

Calls (15K)P/C Ratio: 0.01Puts (4K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: X of Y (Z%)

This setup has occurred 30 times across Health Care in the last 2 years. The average absolute 1-day move is 4.6%, with a raw directional average of +0.1% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Bio-Techne beats expectations, history suggests the stock could rise, potentially by around 6.86% based on past reactions.

In-Line / Cautious

If results are in line with expectations but management's commentary is cautious, the stock may see muted movement as investors reassess their outlook.

Miss

If the company misses expectations, history suggests a potential decline of around 2.11%, reflecting investor disappointment.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

0 buys·3 sells

Members

House only

Est. Notional

$3,003.00–$45,000.00

disclosed dollar ranges

Most Active Members

D-MDApril McClain DelaneyRep.
3

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches in the life sciences sector.
2Management's commentary on operational efficiency improvements.
3Insights into customer engagement strategies and their effectiveness.
4Guidance on revenue growth expectations for the upcoming quarters.
5Responses to market conditions affecting the health care sector.